Systemic Lupus Erythematosus Clinical Trial
Official title:
Fatigue, Depression, and Cortical Excitability Changes in Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic inflammatory autoimmune disease with an unknown
cause and many challenges. Whilst corticosteroids and effective immunosuppressive therapy
have transformed the management of patients with active systemic lupus erythematosus, one of
the major causes of morbidity in Systemic lupus erythematosus patients is chronic,
debilitating fatigue.
Despite frequent occurrence of fatigue in Systemic Lupus Erythematosus, to the best of our
knowledge, no studies have been directly performed to examine fatigue-related changes in
cortical motor function in Systemic lupus erythematosus. In this study, we hypothesized that
Systemic lupus erythematosus patients with fatigue and depression versus Systemic lupus
erythematosus patients without fatigue and depression would present an alteration of motor
cortex excitability.
Fatigue, is a multidimensional phenomenon that affects individuals physically, emotionally,
cognitively, and behaviorally.It affects 80-90% of patients with systemic lupus
erythematosus. It is likely multifactorial and may be caused by disordered sleep, anxiety and
depression, pain, polypharmacy, comorbidities, and possibly disease activity.
Additionally, fatigue is the most prevalent symptom in systemic lupus erythematosus, being
present in up to 90% of patients. Moreover, fatigue has a major impact on the Health-Related
Quality Of Life of Systemic lupus erythematosus patients through its impact on family life,
work, social life, emotional wellbeing, and cognition. Therefore, every effort should be made
to relieve fatigue in this population. Recommendations for the management of fatigue usually
combine pharmacologic and nonpharmacologic interventions; however, no speciļ¬c drugs have
proven useful for treating fatigue in Systemic lupus erythematosus.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
| Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
| Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
| Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
| Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
| Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
| Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
| Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
| Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
| Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
| Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
| Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
| Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
| Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
| Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |